Mita 2007.
Methods | RCT, parallel, (EPA capsules vs nil), 2 years Summary risk of bias: moderate to high |
|
Participants | Japanese type 2 diabetics N: intervention. 40, control: 41 (analysed 30, 30) Level of risk for CVD: moderate Men: 53% intervention, 67% control Mean age in years (SD): 59 (11.2) intervention 61.2 (8.4) control Age range: not reported Smokers: 40% intervention, 43% control Hypertension: not reported Medications taken by at least 50% of those in the control group: oral hypoglycemics Medications taken by 20%‐49% of those in the control group: insulin, lipid lowering drugs, antihypertensives Medications taken by some, but less than 20% of the control group: antithrombotics Location: Japan Ethnicity: 100% Japanese |
|
Interventions | Type: supplement (EPA oil capsules) Comparison: EPA vs nil Intervention: 1800 mg/d EPA EPADEL capsules (Mochida Pharmaceutical Co Ltd Japan)‐ 98% pure ethyl‐ester EPA (unclear how many caps). Dose: ˜1.8 g/d EPA Control: no intervention Compliance: checked during 3 month reviews throughout trial and 5 participants were excluded for poor compliance but no details on method or results Length of intervention: mean 2.1 (0.2) years |
|
Outcomes | Main study outcome: progression of diabetic macroangiopathy measured by carotid intima‐media thickness and brachial‐ankle pulse wave velocity Dropouts: 10 intervention, 11 control Available outcomes: BMI, lipids, BP, HbA1c, cancer diagnosis Response to contact: not yet attempted |
|
Notes | Blood pressure data not used as groups are different at baseline Study funding: not stated |
|
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Low risk | Patients randomly divided into 2 groups matched for age and gender |
Allocation concealment (selection bias) | Unclear risk | No details |
Blinding of participants and personnel (performance bias) All outcomes | High risk | Open label |
Blinding of outcome assessment (detection bias) All outcomes | Low risk | Assessors of main study outcomes were blinded to the treatment |
Incomplete outcome data (attrition bias) All outcomes | Low risk | Dropout rate (26%) over 2 years. All dropouts explained, however, 5 were excluded for poor compliance but no clear predefined protocol for exclusion |
Selective reporting (reporting bias) | Unclear risk | No protocol |
Attention | Low risk | All participants had the same contact |
Compliance | Unclear risk | Compliance measured but no clear methods or reported results |
Other bias | Low risk | None noted |